TY - JOUR
T1 - Using positron emission tomography 2-deoxy-2-[18F]fluoro-D-glucose, 11CO, and 15O-water for monitoring androgen independent prostate cancer.
AU - Kurdziel, Karen A.
AU - Figg, William D.
AU - Carrasquillo, Jorge A.
AU - Huebsch, Susan
AU - Whatley, Millie
AU - Sellers, David
AU - Libutti, Steven K.
AU - Pluda, James M.
AU - Dahut, William
AU - Reed, Edward
AU - Bacharach, Stephen L.
PY - 2003
Y1 - 2003
N2 - PURPOSE: Monitoring of androgen independent prostate cancer (AIPC) therapy involves monitoring prostate specific antigen (PSA) blood serum concentrations; however, the reliability of small changes in PSA values has been questioned. We performed a small pilot study to determine whether PET might be a useful monitor of changes during anti-angiogenic therapy in AIPC. PROCEDURES: Changes in tumor blood flow ([15O] water), blood volume ([11C]CO), 2-deoxy-2-[18F]fluoro-D-glucose (FDG) uptake and metabolic volume were measured before and during thalidomide treatment and compared with changes in PSA in six patients with AIPC. RESULTS: The percent change in PSA correlated with the FDG Delta%SUV(mean) (r=0.94, P<0.01) and Delta%metabolic tumor volume (r=0.91, P<0.01) but less well with Delta%blood volume (r=0.65, P=0.14). Percent change blood flow values showed an inverse correlation with percent changes in PSA (r=-0.83, P=0.032). CONCLUSIONS: PET measures of tumor blood flow and metabolism may have use in monitoring the physiologic changes occurring during anti-angiogenic therapy in AIPC.
AB - PURPOSE: Monitoring of androgen independent prostate cancer (AIPC) therapy involves monitoring prostate specific antigen (PSA) blood serum concentrations; however, the reliability of small changes in PSA values has been questioned. We performed a small pilot study to determine whether PET might be a useful monitor of changes during anti-angiogenic therapy in AIPC. PROCEDURES: Changes in tumor blood flow ([15O] water), blood volume ([11C]CO), 2-deoxy-2-[18F]fluoro-D-glucose (FDG) uptake and metabolic volume were measured before and during thalidomide treatment and compared with changes in PSA in six patients with AIPC. RESULTS: The percent change in PSA correlated with the FDG Delta%SUV(mean) (r=0.94, P<0.01) and Delta%metabolic tumor volume (r=0.91, P<0.01) but less well with Delta%blood volume (r=0.65, P=0.14). Percent change blood flow values showed an inverse correlation with percent changes in PSA (r=-0.83, P=0.032). CONCLUSIONS: PET measures of tumor blood flow and metabolism may have use in monitoring the physiologic changes occurring during anti-angiogenic therapy in AIPC.
UR - http://www.scopus.com/inward/record.url?scp=5444229812&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=5444229812&partnerID=8YFLogxK
U2 - 10.1016/S1536-1632(03)00039-8
DO - 10.1016/S1536-1632(03)00039-8
M3 - Article
C2 - 14499149
AN - SCOPUS:5444229812
SN - 1536-1632
VL - 5
SP - 86
EP - 93
JO - Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging
JF - Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging
IS - 2
ER -
